AMENDED AND RESTATED Joint venture, research COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 18th, 2019 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations • California
This Amended and Restated Joint Venture, Research Collaboration And License Agreement (this “Agreement”) is entered into as of July ___, 2018 (the “Restatement Date”), by and between Providence Therapeutics Inc., a corporation incorporated under the laws of Alberta, Canada having a registered address at MaRS Centre, West Tower, 661 University Ave, Suite 1300, Toronto, Ontario, Canada (“Providence”), and Arcturus Therapeutics, Inc., a Delaware corporation with its principal place of business located at 10628 Science Center Drive, Suite 250, CA 92121, USA (“Arcturus”). Arcturus and Providence are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • March 18th, 2019 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations • New York
This Research Collaboration Agreement is entered into and effective as of March 8, 2019 (the “Effective Date”), by and between Arcturus Therapeutics, Inc. (“Arcturus”), a Delaware corporation, having offices at 10628 Science Center Drive, Suite 250, San Diego, CA 92121 and MILLENNIUM PHARMACEUTICALS, INC. (“Takeda”), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and a Delaware corporation organized under the laws of Delaware, having offices at 40 Landsdowne Street, Cambridge, MA 02139, collectively the “Parties” and respectively the “Party”.
AGREEMENT drawn up and signed on February 8, 2019Agreement • March 18th, 2019 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations
Whereas the Israeli Company is a public company incorporated in Israel and whose shares are listed for trading on the NASDAQ;
